What's in Intra-Cellular Therapies's pipeline?

Intra-Cellular Therapies has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Intra-Cellular Therapies's portfolio?

Top competitors by shared drug class: , AbbVie, Alkermes Inc, Eli Lilly, Hisamitsu.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/intra-cellular.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Intra-Cellular Therapies — Portfolio Competitive Intelligence Brief

Intra-Cellular Therapies (ITCI) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ITCI (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Caplyta	LUMATEPERONE	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 2A	Neuroscience	2019-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
AbbVie · 1 shared drug class
Alkermes Inc · 1 shared drug class
Eli Lilly · 1 shared drug class
Hisamitsu · 1 shared drug class
Jazz Pharmaceuticals · 1 shared drug class
Johnson & Johnson (Janssen) · 1 shared drug class
Otsuka · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Intra-Cellular Therapies:

Cite this brief

Drug Landscape (2026). Intra-Cellular Therapies — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/intra-cellular. Accessed 2026-05-15.